BV After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03540849
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
58
Enrollment
OTHER
Sponsor class
Conditions
Hodgkin Lymphoma
Interventions
DRUG:
Brentuximab Vedotin (Bv)
Sponsor
University Hospital, Caen